Effect of estrogen replacement therapy on the specificity and sensitivity of screening mammography

Journal of the National Cancer Institute

Volumn 88, Issue 10, 1996, Pages 643-649

  Laya, Mary B ^a   Larson, Eric B ^a   Taplin, Stephen H ^b   White, Emily ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAMMOGRAPHY; POSTMENOPAUSE; RETROSPECTIVE STUDY;

AGED; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MAMMOGRAPHY; MASS SCREENING; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY;

EID: 0029916295     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.10.643     Document Type: Article

References (54)

1. Fletcher SW, Black W, Harris R, Rimer B, Shapiro S. Report of the International Workshop on Screening for Breast Cancer [see comment citation in Medline]. J Natl Cancer Inst 1993;85:1644-56.
2. Shapiro S, Venet W, Strax P, Venet L, Roeser R. Ten- to fourteen-year effect of screening on breast cancer mortality. J Natl Cancer Inst 1982; 69:349-55.
3. Andersson I, Aspegren K, Janzon L, Landberg T, Lindholm K, Linell F, et al. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. BMJ 1988;297:943-8.
4. Tabar L, Fagerberg CJ, Cad A, Baldetorp L, Holmberg LH, Grontoft O, et al. Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the Breast Cancer Screening Working Group of the Swedish National Board of Health and Welfare. Lancet 1985;1:829-32.
5. Roberts MM, Alexander FE, Anderson TJ, Chetty V, Donnan PT, Forrest P, et al. Edinburgh trial of screening for breast cancer: mortality at seven years [see comment citations in Medline). Lancet 1990;335:241-6.
6. Frisell J, Eklund L, Hellstrom L, Lidbrink E, Rutqvist LE, Somell A. Randomized study of mammography screening - preliminary report on mortality in the Stockholm trial. Breast Cancer Res Treat 1991;18:49-56.
7. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Cancer Screening Study: 2. Breast cancer detection and death rates among women aged 50-59 years. Can Med Assoc J 1992;147:1477-1594.
8. Kerlikowske K, Grady D, Barclay J, Sickles EA, Eaton A, Ernster V. Positive predictive value of screening mammography by age and family history of breast cancer [see comment citation in Medline]. JAMA 1993;270: 2444-50.
9. Fajardo LL, Hillman BJ, Frey C. Correlation between breast parenchymal patterns and mammographers' certainty of diagnosis. Invest Radiol 1988; 23:505-8.
10. Grove JS, Goodman MJ, Gilbert FI Jr, Mi MP. Factors associated with mammographic pattern. Br J Radiol 1985;58:21-5.
11. Whitehouse GH, Leinster SJ. The variation of breast parenchymal patterns with age. Br J Radiol 1985;58:315-8.
12. Anderson TJ. Effects on breast tissue of exogenous oestrogens and progestogens. Acta Obstet Gynecol Scand Suppl 1986;134:9-13.
13. Saftlas AF, Hoover RN, Brinton LA, Szklo M, Oison DR, Salane M, et al. Mammographic densities and risk of breast cancer [see comment citation in Medline]. Cancer 1991;67:2833-8.
14. Kerlikowske K, Grady D, Barclay J, Sickles EA, Ernster V. Do age and density affect breast cancer detection by first screening mammography? J Gen Intern Med 1995;10(suppl):44.
15. Feig SA, Shaber GS, Patchefsky A, Schwartz GF, Edeiken J, Libshitz HI, et al. Analysis of clinically occult and mammographically occult breast tumors. AJR Am J Roentgenol 1977;128:403-8.
16. Ma L, Fishell E, Wright B, Hanna W, Allan S, Boyd NF. Case-control study of factors associated with failure to detect breast cancer by mammography [see comment citation in Medline]. J Natl Cancer Inst 1992;84:781-5.
17. Bird RE, Wallace TW, Yankaskas BC. Analysis of cancer missed at screening mammography. Radiology 1992;184:613-7.
18. Miller AB, Baines CJ, To T, Wall C. Canadian National Breast Cancer Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years [published erratum appears in Can Med Assoc J 1993;148:718] [see comment citations in Medline]. Can Med Assoc J 1992,147:1459-76.
19. Tabar L, Fagerberg G, Duffy SW, Day NE, Gad A, Grontoft O. Update of the Swedish two-county program of mammographic screening for breast cancer. Radiol Clin North Am 1992;30:187-210.
20. Peeters PH, Verbeek AL, Hendriks JH, van Bon MJ. Screening for breast cancer in Nijmegen. Report of 6 screening rounds, 1975-1986. Int J Cancer 1989;43:226-30.
21. Stomper PC, Van Voorhis BJ, Ravnikar VA, Meyer JE. Mammographic changes associated with postmenopausal hormone replacement therapy: a longitudinal study. Radiology 1990;174:487-90.
22. Kaufman Z, Garstin WI, Hayes R, Michell MJ, Baum M. The mammographic parenchymal patterns of women on hormonal replacement therapy. Clin Radiol 1991;43:389-92.
23. Berkowitz, JE, Gatewood OM, Goldblum LE, Gayler BW. Hormonal replacement therapy: mammographic manifestations. Radiology 1990;174: 199-201.
24. McNicholas MM, Heneghan JP, Milner MH, Tunney T, Hourihane JB, MacErlaine DP. Pain and increased mammographic density in women receiving hormone replacement therapy: a prospective study. AJR Am J Roentgenol 1994;163:311-5.
25. Laya MB, Gallagher JC, Schreiman JS, Larson EB, Watson P, Weinstein L. Effect of postmenopausal hormonal replacement therapy on mammographic density and parenchymal pattern. Radiology 1995;196:433-7.
26. Carter AP, Thompson RS, Bourdeau RV, Andenes J, Mustin H, Straley H. A clinically effective breast cancer screening program can be cost-effective, too. Prev Med 1987;16:19-34.
27. Taplin SH, Thompson RS, Schnitzer F, Anderman C, Immanuel V. Revisions in the risk-based Breast Cancer Screening Program at Group Health Cooperative [published erratum appears in Cancer 1991;67:2400]. Cancer 1990;66:812-8.
28. Taplin SH, Barlow W, Urban N, Mandelson MT, Timlin D, Ichikawa L, et al. Stage, age, comorbidity, and direct costs of colon, prostate, and breast cancer care [see comment citation in Medline). J Natl Cancer Inst 1995; 87:417-26.
29. Sox HC. Probability theory and the interpretation of diagnostic tests. In: Sox HC, editor. Common diagnostic tests: uses and interpretation. 2d ed. Philadelphia: American College of Physicians, 1990.
30. Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. Lyon, France: IARC Sci Publ 32, 1980.
31. Grove JS, Goodman MJ, Gilbert FI Jr, Mi MP. Factors associated with mammographic pattern. Br J Radiol 1985;58:21-5.
32. Buchanan JB, Weisburg BF, Sandoz JP, Gray LA Sr, Bland KI. Selected prognostic variables for mammographic parenchymal patterns. Cancer 1981;47:2135-7.
33. Gravelle IH, Bulstrode JC, Bulbrook RD, Hayward JL, Wang DY. The relationship between radiological patterns of the breast and body weight and height. Br J Radiol 1982;55:23-5.
34. de Stavola BL, Gravelle IH, Wang DY, Allen DS, Bulbrook RD, Fentiman IS. Relationship of mammographic parenchymal patterns with breast cancer risk factors and risk of breast cancer in a prospective study. Int J Epidemiol 1990;19:247-54.
35. Jackson VP, Hendrick RE, Feig SA, Kopans DB. Imaging of the radiographically dense breast. Radiology 1993;188:297-301.
36. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer [see comment citations in Medline]. Arch Intern Med 1991;151:67-72.
37. Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer (published erratum appears in JAMA 1991;266:1362] [see comment citations in Medline]. JAMA 1991;265: 1985-90.
38. Herrinton LJ, Saftlas AF, Stanford JL, Brinton LA, Wolfe JN. Do alcohol intake and mammographic densities interact in regard to the risk of breast cancer? Cancer 1993;71:3029-35.
39. Funkhouser E, Waterbor JW, Cole P, Rubin E. Mammographic pattern and breast cancer risk among women having elective screening. South Med J 1993;86:177-80.
40. White E, Urban N, Taylor V. Mammography utilization, public health impact, and cost-effectiveness in the United States. Annu Rev Public Health 1993;14:605-33.
41. Eddy DM, Hasselblad V, McGivney W, Hendee W. The value of mammography screening in women under age 50 years. JAMA 1988;259: 1512-9.
42. Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF. Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 1991;114:657-61.
43. Baines CJ, To T, Wall C. Women's attitudes to screening after participation in the National Breast Screening Study. A questionnaire survey. Cancer 1990;65:1663-9.
44. Fentiman IS. Pensive women, painful vigils: consequences of delay in assessment of mammographic abnormalities. Lancet 1988;1:1041-2.
45. Devitt JE. False alarms of breast cancer [see comment citations in Medline]. Lancet 1989;2:1257-8.
46. Kuni CC. Mammography in the 1990s: a plea for objective doctors and informed patients. Am J Prev Med 1993;9:185-90.
47. Weiss NS, Ure CL, Ballard JH, Williams AR, Daling JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195-8.
48. Ettinger B, Genant HK, Cann CE. Long-term estrogen replacement therapy prevents bone loss and fractures. Ann Intern Med 1985;102:319-24.
49. Riggs BL, Melton LJ. The prevention and treatment of osteoporosis [published erratum appears in N Engl J Med 1993;328:65] [see comment citations in Medline]. N Engl J Med 1992;327:620-7.
50. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, et al. Postmenopausal estrogen therapy and cardiovascular disease. Tenyear follow-up from the Nurses' Health Study [see comment citations in Medline]. N Engl J Med 1991;325: 756-62.
51. Barrett-Connor E, Bush TL. Estrogen and coronary heart disease in women [see comment citation in Medline]. JAMA 1991;265:1861-7.
52. Lobo RA. Cardiovascular implications of estrogen replacement therapy. Obstet Gynecol 1990;75(4 Suppl): 18s-25s.
53. Psaty BM, Heckbert SR, Atkins D, Siscovick DS, Koepsell TD, Wahl PW, et al. A review of the association of estrogens and progestins with cardiovascular disease in postmenopausal women. Arch Intern Med 1993;153: 1421-7.
54. Simonsen LL. Top 200 drugs. Pharmacy Times 61:17-23.